Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
- Careers
Find your place at Lilly with Lilly Careers. For more than a...
- Investor Relations
Lilly collaborates with OpenAI to discover novel medicines...
- Login
Connecting to Lilly. The following services are available to...
- Trials
Lilly is committed to the discovery, research and...
- Annual Reports
Search Lilly.com For Content... Annual Reports Annual...
- Individual Investors
EQ Shareowner Services administers the Shareowner Service...
- Quarterly Results
Search Lilly.com For Content... Quarterly Results Quarterly...
- Webcasts & Presentations
Speaker: Patrik Jonsson, Executive Vice President, President...
- Careers
Creating Medicines to Make Lives Better. Lilly unites caring with discovery to create medicines that make life better for people around the world.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
People also ask
What does Lilly Do?
What is Lilly's new approach to clinical trials?
Where is Eli Lilly based?
When did Lilly become a company?
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Jun 25, 2024 · This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and OpenAI, Lilly's research and development strategy, and potential payments to OpenAI in connection with the collaboration and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research ...
May 24, 2024 · Eli Lilly and Company announced a $9 billion expansion of its Lebanon, Indiana, site to produce active pharmaceutical ingredients for Zepbound and Mounjaro, two synthetic medicines for obesity and type 2 diabetes. The company also invested more than $16 billion in other U.S. and European facilities since 2020.
Eli Lilly, along with its Danish rival Novo Nordisk, has developed a considerable lead over the rest of the pharmaceutical industry when it comes to obesity medication.